ReviewNeurology2022
Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
Review in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Aerobic walking exercise training boosts thalamic connectivity in MS patients with cognitive processing speed impairment.Brain and cognition · 2025Trial
- Addressing the Global Disparities in Access to Treatment in Spinal Muscular Atrophy.Muscle & nerve · 2026Review
- Medication adherence in hypertension and diabetes comorbidity: implications for disease control in a population-based study.Frontiers in public health · 2026Article
- Review
- B-Cell-Targeted Therapies for Black vs White Americans with Relapsing Multiple Sclerosis.Ethnicity & disease · 2025Observational
- Influence of race and gender on variability in clinical decision-making in neurology.Scientific reports · 2025Article
- Early intensive therapy versus escalation strategy in French Caribbean multiple sclerosis cohort.European journal of neurology · 2025Article
- Impact of paramagnetic rim lesions on disability and race in multiple sclerosis: mediation analysis.Annals of clinical and translational neurology · 2024Observational
- Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.Journal of neurology · 2024Review
- Podcast on Identifying and Understanding Barriers to Care in Underserved Populations With MS in the United States.Neurology and therapy · 2024Article
- Imaging phenotypic differences in multiple sclerosis: at the crossroads of aging, sex, race, and ethnicity.Frontiers in global women's health · 2024Review
- Lifetime stressors relate to invisible symptoms of multiple sclerosis.Exploration of neuroprotective therapy · 2024Article
- Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis.Drugs - real world outcomes · 2023Article
- Disparities in Huntington Disease Severity: Analysis Using the ENROLL-HD Dataset.Neurology. Clinical practice · 2023Article
- The interaction between Epstein-Barr virus and multiple sclerosis genetic risk loci: insights into disease pathogenesis and therapeutic opportunities.Clinical & translational immunology · 2023Review
- Do magnetic resonance imaging features differ between persons with multiple sclerosis of various races and ethnicities?Frontiers in neurology · 2023Review
- Race- and place-based disparities in multiple sclerosis care: A qualitative study of patient experiences.Multiple sclerosis journal - experimental, translational and clinicalArticle
- Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS have a different clinical presentation, increased disease incidence and burden, and worse long-term outcomes vs their White counterparts. Due to limited data available for African Americans in MS clinical trials, it is difficult to make informed, generalizable conclusions about the natural history, prognosis, and therapeutic response in this population. In this narrative review, we highlight the nature and magnitude of the health disparities experienced by African Americans with MS and underscore the pressing need to increase knowledge about and understanding of MS disease manifestations in this group. In addition, we describe the mission and objectives of the recently established National African Americans with Multiple Sclerosis Registry, which is intended to be a platform to advance the care of African Americans with MS and address health disparities they may experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.